(19)
(11) EP 2 054 074 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.11.2014 Bulletin 2014/46

(45) Mention of the grant of the patent:
01.10.2014 Bulletin 2014/40

(21) Application number: 07812992.1

(22) Date of filing: 16.07.2007
(51) International Patent Classification (IPC): 
C07K 14/505(2006.01)
 A61K 38/00(2006.01)
(86) International application number:
PCT/US2007/073629
(87) International publication number:
WO 2008/019214 (14.02.2008 Gazette 2008/07)

(54)

MODIFIED ERYTHROPOIETIN

MODIFIZIERTES ERYTHROPOIETIN

ERYTHROPOÏÉTINE MODIFIÉE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: 04.08.2006 US 835429 P

(43) Date of publication of application:
06.05.2009 Bulletin 2009/19

(73) Proprietor: Prolong Pharmaceuticals, LLC
South Plainfield, NJ 07080 (US)

(72) Inventors:
  • ABUCHOWSKI, Abraham
    Califon, NJ 07830 (US)
  • LEE, Lihysyng Stanford
    Cranbury, New Jersey 08512 (US)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)


(56) References cited: : 
EP-A- 1 333 036
WO-A1-2004/009627
WO-A2-03/029291
US-A1- 2004 266 690
US-A1- 2005 147 661
 WO-A-2004/091494
WO-A2-02/49673
WO-A2-2006/089228
US-A1- 2004 266 690
US-A1- 2005 159 353
   
  • LONG D L ET AL: "Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 34, no. 6, 1 June 2006 (2006-06-01), pages 697-704, XP025017483, ISSN: 0301-472X, DOI: DOI:10.1016/J.EXPHEM.2006.02.011 [retrieved on 2006-06-01]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).